ADVERTISEMENT
Saturday, January 28, 2023
  • Home
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions
Involve Africa
  • Home
  • All African News
  • Politics
  • Technology
  • Entertainment News
    • Travel
    • Tourism
    • Arts
  • Finance
    • Food & Agriculture
    • Business & Economy
  • Crypto News
  • Energy & Environment
No Result
View All Result
  • Home
  • All African News
  • Politics
  • Technology
  • Entertainment News
    • Travel
    • Tourism
    • Arts
  • Finance
    • Food & Agriculture
    • Business & Economy
  • Crypto News
  • Energy & Environment
No Result
View All Result
Involve Africa
No Result
View All Result
ADVERTISEMENT
Home Business & Economy

A billionaire wants to shake up America’s drugs market

Involve Africa by Involve Africa
June 26, 2022
in Business & Economy
0
A billionaire wants to shake up America’s drugs market
585
SHARES
3.2k
VIEWS
https://web.facebook.com/involveafricanews?_rdc=1&https://twitter.com/involveafricanews


If there is one thing guaranteed to get Americans to stand to attention it is cheap Viagra. On June 2nd a firm owned by Mark Cuban, a billionaire investor (as well as a judge on “Shark Tank”, a tv show for budding entrepreneurs, and the owner of an nba basketball team), caused a stir by reducing the price of the blue pill—whose patent expired two years ago—from several dollars a pop to 11 cents. It was one of 87 drugs that the Mark Cuban Cost Plus Drug Company added to its growing assortment of cheap off-patent medicines. A new study finds that Mr Cuban’s prices might have saved Medicare, a federal health scheme for the elderly, $3.6bn on $9.6bn-worth of drugs it had bought in 2020.

Listen to this story.
Enjoy more audio and podcasts on iOS or Android.

Your browser does not support the <audio> element.

Save time by listening to our audio articles as you multitask

Drugs in America are notoriously dear. In 2019 spending on prescription medicines came to $1,126 per citizen, twice the figure in other rich counties (see chart). Critics like Mr Cuban seek to shake things up. He intends to offer thousands of cheaper drugs by the end of the year. His company buys these directly from manufacturers and sells them to consumers at cost, plus a 15% mark-up and a $3 pharmacy fee. The idea is to make drugs affordable to the 31m Americans who lack health insurance and the many more whose policies make them pay hefty fees for prescriptions. Patients have thanked him on social media for slashing the cost of drugs to treat conditions ranging from heartburn to cancer.

Mr Cuban is not the only one to have lost patience with America’s current set-up. CivicaScript, from Lehi, Utah, is also trying to bring down the price of generics. In March it said it would manufacture a generic insulin at no more than $30 a vial, down from $300 for today’s branded versions. At the innovative, patented end of the market, meanwhile, eqrx and Checkpoint Therapeutics are developing new cancer and immunology drugs with the explicit intention of undercutting expensive existing therapies from big pharma.

Competing on price seems like an obvious thing to try in America’s overpriced drug market. A lack of such competition suggests that obstacles get in the way.

Some of these are practical. Certain off-patent drugs take years to copy, manufacture, test and win regulatory approval. Insulin, a complicated biological molecule, is one of them. Having borne the expense of copying and certifying its insulin, CivicaScript may find that the incumbents, which have long since recouped their development costs, simply lower the price of their branded products to undercut it instead. Ned McCoy, CivicaScript’s boss, insists this would make him happy; the firm’s goal, he says, is to bring about change in the market. The firm is set up as a public-benefit corporation that is not seeking profits but rather a “positive impact on society”. But it cannot do that if it goes out of business.

In the American market for patented medicines, the drug’s inventor has a great deal of pricing power, which has driven prices higher. Developing new therapies is a costly gauntlet of research, clinical trials and regulatory hurdles. All too often it ends in failure. Risks can be reduced by picking well-understood diseases. Nevertheless, to succeed in the long run, eqrx will need to make up with volume what it forgoes on margins, observes Daniel Chancellor of Informa Pharma Intelligence, a research firm. The same applies to others who choose this model, like Checkpoint. Britain’s government has indicated that it would make large-scale purchases from eqrx’s pipeline of cancer drugs if those gain regulatory approval. Though this will not help American patients in the near term, it is good news for the company if it helps scale up production.

The final wrinkle is that any medicine-seller who undercuts incumbents becomes a target for acquisition by them. It is easy to imagine a pharma giant launching a takeover bid for the firm, and if successful simply jacking up prices to what the market will bear—which in America is a lot more than what eqrx wants to charge. After buying a biotech startup that had developed a hepatitis drug in 2011, one big drugmaker, Gilead, charged much more for the treatment than its target had planned.

On June 13th Goldman Sachs, an investment bank, noted that the market was undervaluing the drugs being developed by eqrx. On the topic of being acquired, eqrx’s boss, Melanie Nallicheri, remarks cryptically that the firm has put thought into how “not to let that happen”, but declines to give details. Mr Cuban shares the sentiment: “I don’t have a reason to sell…I can afford to absorb the losses that come from starting the company.” CivicaScript, too, has made itself an unattractive investment by ceding control over a lot of what it can do to a second non-profit sister company, Civica. The poison pill, it seems, has a place in the pharma business. ■

For more expert analysis of the biggest stories in economics, business and markets, sign up to Money Talks, our weekly newsletter.



Source_link

You might also like

Boom In HRTech M&A With $11 Billion Investment Reveals Hampleton Partners

Total Telecom takes highly successful Connected event series to the U.S.

Africa: AI Tool ‘98% Correct’ to Predict Mosquitoes’ Age

Previous Post

Is eastern Africa’s drought the worst in recent history? And are worse yet to come?

Next Post

South Africa’s petrol price could hit R40 a litre: analysts

Involve Africa

Involve Africa

Related Posts

Boom In HRTech M&A With $11 Billion Investment Reveals Hampleton Partners
Business & Economy

Boom In HRTech M&A With $11 Billion Investment Reveals Hampleton Partners

by Involve Africa
January 28, 2023
Total Telecom takes highly successful Connected event series to the U.S.
Business & Economy

Total Telecom takes highly successful Connected event series to the U.S.

by Involve Africa
January 27, 2023
Africa: AI Tool ‘98% Correct’ to Predict Mosquitoes’ Age
Business & Economy

Africa: AI Tool ‘98% Correct’ to Predict Mosquitoes’ Age

by Involve Africa
January 27, 2023
Nigeria: Officer Who ‘Shot’ Bolanle Raheem Attempted to Flee From Scene, Police Witness Tells Court
Business & Economy

Nigeria: Officer Who ‘Shot’ Bolanle Raheem Attempted to Flee From Scene, Police Witness Tells Court

by Involve Africa
January 26, 2023
How will Satya Nadella handle Microsoft’s ChatGPT moment?
Business & Economy

How will Satya Nadella handle Microsoft’s ChatGPT moment?

by Involve Africa
January 26, 2023
Next Post
South Africa’s petrol price could hit R40 a litre: analysts

South Africa’s petrol price could hit R40 a litre: analysts

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

The best, worst and weirdest art by musicians-turned-painters

The best, worst and weirdest art by musicians-turned-painters

September 8, 2022
9 Things That Are Free in November

9 Things That Are Free in November

November 1, 2022

Categories

  • All African News
  • Arts
  • Business & Economy
  • Crypto News
  • Energy & Environment
  • Entertainment News
  • Finance
  • Food & Agriculture
  • News Videos
  • Politics
  • Technology
  • Tourism
  • Travel

Don't miss it

Sergey Lavrov to Choose between Illusions and Reality for Africa
Food & Agriculture

Sergey Lavrov to Choose between Illusions and Reality for Africa

January 28, 2023
Black Cowboys Ride into History at the African American Museum in Dallas – NBC 5 Dallas-Fort Worth
All African News

Black Cowboys Ride into History at the African American Museum in Dallas – NBC 5 Dallas-Fort Worth

January 28, 2023
Core Scientific files motion to sell over $6M in Bitmain coupons
Crypto News

Core Scientific files motion to sell over $6M in Bitmain coupons

January 28, 2023
Yaa Pono drags Sarkodie in his new song “Yard”(WATCH)
Entertainment News

Yaa Pono drags Sarkodie in his new song “Yard”(WATCH)

January 28, 2023
Bottomline Africa: Reproductive Health Bill
News Videos

Bottomline Africa: Reproductive Health Bill

January 28, 2023
How To Report 2022 Mega Backdoor Roth In H&R Block (Updated)
Finance

How To Report 2022 Mega Backdoor Roth In H&R Block (Updated)

January 28, 2023

Social Bar

Welcome to involve Africa The goal of involve Africa is to give you the absolute best news sources for any topic! Our topics are carefully curated and constantly updated as we know the web moves fast so we try to as well.

Categories

  • All African News
  • Arts
  • Business & Economy
  • Crypto News
  • Energy & Environment
  • Entertainment News
  • Finance
  • Food & Agriculture
  • News Videos
  • Politics
  • Technology
  • Tourism
  • Travel

Site Links

  • Home
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

Recent News

Sergey Lavrov to Choose between Illusions and Reality for Africa

Sergey Lavrov to Choose between Illusions and Reality for Africa

January 28, 2023
Black Cowboys Ride into History at the African American Museum in Dallas – NBC 5 Dallas-Fort Worth

Black Cowboys Ride into History at the African American Museum in Dallas – NBC 5 Dallas-Fort Worth

January 28, 2023

INVOLVEAFRICA.COM

No Result
View All Result
  • Home
  • All African News
  • Politics
  • Technology
  • Entertainment News
    • Travel
    • Tourism
    • Arts
  • Finance
    • Food & Agriculture
    • Business & Economy
  • Crypto News
  • Energy & Environment

INVOLVEAFRICA.COM

What Are Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT